280 related articles for article (PubMed ID: 27263787)
21. Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy.
Yamaguchi W; Yui N; Nagao T; Oshikawa G; Negi M; Iimori S; Okado T; Rai T; Uchida S
Intern Med; 2016; 55(3):263-8. PubMed ID: 26831021
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
Malani AK; Gupta V; Rangineni R
Acta Haematol; 2006; 116(4):255-8. PubMed ID: 17119326
[TBL] [Abstract][Full Text] [Related]
23. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Ludwig H; Zojer N
Nat Rev Clin Oncol; 2010 May; 7(5):289-94. PubMed ID: 20351701
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
[TBL] [Abstract][Full Text] [Related]
25. Management of myeloma-associated renal dysfunction in the era of novel therapies.
Gaballa MR; Laubach JP; Schlossman RL; Redman K; Noonan K; Mitsiades CS; Ghobrial IM; Munshi N; Anderson KC; Richardson PG
Expert Rev Hematol; 2012 Feb; 5(1):51-66; quiz 67-8. PubMed ID: 22272706
[TBL] [Abstract][Full Text] [Related]
26. Outcome of patients with multiple myeloma and renal failure on novel regimens.
Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
28. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Renal Impairment of Multiple Myeloma Collaborative Study Group
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
[TBL] [Abstract][Full Text] [Related]
30. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
Dimopoulos MA; Terpos E; Goldschmidt H; Alegre A; Mark T; Niesvizky R
Cancer Treat Rev; 2012 Dec; 38(8):1012-9. PubMed ID: 22609463
[TBL] [Abstract][Full Text] [Related]
31. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
[TBL] [Abstract][Full Text] [Related]
32. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
Sekiguchi Y; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2015; 8(8):9609-19. PubMed ID: 26464727
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
34. [Achievement of a stringent complete response with low-dose pomalidomide monotherapy in a multiple myeloma patient].
Endo T; Hamada T; Otake S; Nakagawa M; Uchino Y; Takahashi H; Miura K; Iriyama N; Koike T; Kurihara K; Sato H; Hatta Y; Takei M
Rinsho Ketsueki; 2018; 59(4):395-400. PubMed ID: 29743398
[TBL] [Abstract][Full Text] [Related]
35. Current therapy of myeloma induced renal failure.
Gertz MA
Leuk Lymphoma; 2008 May; 49(5):833-4. PubMed ID: 18452070
[No Abstract] [Full Text] [Related]
36. [Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma].
Liu HB; Chen LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):498-501. PubMed ID: 27151018
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
Costa LJ; Abbas J; Ortiz-Cruz KL; Kang Y; Stuart RK
Eur J Haematol; 2012 Nov; 89(5):432-4. PubMed ID: 22971164
[No Abstract] [Full Text] [Related]
38. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
[TBL] [Abstract][Full Text] [Related]
39. Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Gladney SP; Lonial S; Kaufman JL
Clin Lymphoma Myeloma; 2008 Feb; 8(1):52-4. PubMed ID: 18501088
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
